Xanthines

• 

  Subject Areas on Research

  • ATP hydrolysis by a CFTR domain: pharmacology and effects of G551D mutation. 
  • Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. 
  • Acute decompensated heart failure: update on new and emerging evidence and directions for future research. 
  • Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. 
  • Acute heart failure in the young: Clinical characteristics and biomarker profiles. 
  • Adenine nucleotides of ischemic intestine do not reflect injury. 
  • Adenosine triphosphate activates ion permeabilities in biliary epithelial cells. 
  • Biochemical actions of follice-stimulating hormone in the sertoli cell of the rat testis. 
  • Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. 
  • Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. 
  • Computed tomography of urinary calculi. 
  • Coupled events in the early biochemical actions of FSH on the Sertoli cells of the testis. 
  • Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. 
  • Diuretic response in acute heart failure: clinical characteristics and prognostic significance. 
  • Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. 
  • Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. 
  • Effect of conformation on the binding of flavins to flavoenzymes. 
  • Effects of BG9928, an adenosine A₁ receptor antagonist, in patients with congestive heart failure. 
  • Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). 
  • HEPATIC ALDEHYDE OXIDASE. 3. THE SUBSTRATE-BINDING SITE. 
  • Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. 
  • Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. 
  • Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. 
  • Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. 
  • International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. 
  • Methylxanthines as adenosine receptor antagonists. 
  • MicroRNAs relate to early worsening of renal function in patients with acute heart failure. 
  • Modulation of basal L-type Ca2+ current by adenosine in ferret isolated right ventricular myocytes. 
  • Molecular basis of the biological function of molybdenum. Molybdenum-free xanthine oxidase from livers of tungsten-treated rats. 
  • Nonequivalence of the flavin adenine dinucleotide moieties of chicken liver xanthine dehydrogenase. 
  • Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. 
  • Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes. 
  • Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. 
  • Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data. 
  • Protein phosphatases mediate depotentiation induced by high-intensity theta-burst stimulation. 
  • Regulation of gamma-aminobutyric acid/barbiturate receptor-gated chloride ion flux in brain vesicles by phospholipase A2: possible role of oxygen radicals. 
  • Renal function trajectories and clinical outcomes in acute heart failure. 
  • Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial. 
  • Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. 
  • STRUCTURE AND FUNCTION OF IRON-FLAVOPROTEINS. 
  • Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). 
  • Simultaneous determination of guanine, uric acid, hypoxanthine and xanthine in human plasma by reversed-phase high-performance liquid chromatography with amperometric detection. 
  • Superoxide-independent platelet response to xanthine oxidase. 
  • Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A2 receptors on rat Kupffer cells. 
  • Testicular adenosine 3':5'-monophosphate-dependent protein kinase. Regulation by follicle-stimulating hormone. 
  • The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. 
  • The disconnect between phase II and phase III trials of drugs for heart failure. 
  • The effect of xanthine/xanthine oxidase generated reactive oxygen species on synaptic transmission. 
  • The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study. 
  • The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. 
  • Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. 
  • Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. 
  • Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology